Show simple item record

dc.contributor.authorTurner, N
dc.contributor.authorAlarcón, E
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorPhilco, M
dc.contributor.authorLópez Chuken, Y
dc.contributor.authorSablin, M-P
dc.contributor.authorTamura, K
dc.contributor.authorGomez Villanueva, A
dc.contributor.authorPérez-Fidalgo, J
dc.contributor.authorFoxley, A
dc.contributor.authorLindemann, J
dc.contributor.authorMaudsley, R
dc.contributor.authorOuthwaite, E
dc.contributor.authorPass, M
dc.contributor.authorRugman, P
dc.contributor.authorSchiavon, G
dc.contributor.authorOliveira, M
dc.date.accessioned2017-11-22T21:32:53Z
dc.date.available2017-11-22T21:32:53Z
dc.date.issued2017-09
dc.identifier.citation241PD BEECH: a randomised phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdx365.004
dc.identifier.urihttp://hdl.handle.net/10541/620665
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx365.004/4108470/241PDBEECH-A-randomised-Phase-2-study-assessingen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title241PD BEECH: a randomised phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
dc.typeMeetings and Proceedingsen
dc.contributor.department"Molecular Oncology, The Institute of Cancer Research and The Royal Marsden NHSen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record